Navigation Links
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
Date:8/14/2014

the comparable period in 2013. The decrease of $1.2 million is due to due changes in the Company's closing common stock price on the dividend payment dates and the number of preferred shares earning dividends each quarter.

Preferred stock dividends were $3.0 million for the six months ended June 30, 2014, compared to $5.9 million for the comparable period in 2013. The decrease of $2.9 million is due to due changes in the Company's closing common stock price on the dividend payment dates and the number of preferred shares earning dividends each quarter.

About RXi Pharmaceuticals CorporationRXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi (sd-rxRNA®) platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate the expression of specific genes that may be over-expressed in disease conditions. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the Company's Scientific Advisory Board, RXi's first RNAi product candidate, RXI-109, entered into human clinical trials in June 2012 and is currently being evaluated in Phase 2 clinical trials to reduce dermal scarring (fibrosis).  RXI-109 is also being evaluated in pre-clinical studies for retinal scarring.  RXI-109 targets connective tissue growth factor (CTGF), a key player in development of dermal scarring, retinal scarring and fibrosis. RXi's sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and ant
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  The Council ... entrepreneurial support organization in the country, today released ... Report . It showed that ... North Carolina startups in the technology, ... more global investment from a variety of sources. Significant ...
(Date:9/16/2014)... Sept. 16, 2014 /PRNewswire-iReach/ -- Researchers found that ... identifies patients with bone fragility fracture when today,s ... people worldwide are at risk of fracture for ... bone strength test, the DEXA bone density scan. ... for Bone and Mineral Research Annual Conference (ASBMR) ...
(Date:9/16/2014)... RENU 28, the world's first and only skin gel ... in Australia and New Zealand in mid-August . , The ... tour will make stops in Brisbane on September 16, the ... on the 20th, and Melbourne on the 22nd. , Helping ... to educate people about the new product and business opportunity ...
(Date:9/15/2014)... JOSE, Calif. , Sept. 15, 2014 /PRNewswire/ ... Proposals (RFP) for flexible, printed product demonstrators (demos) ... a two-stage RFP process with pre-proposals due on ... January 2015.  Funds for proposals ultimately selected are ... and have a significant cost share by the ...
Breaking Biology Technology:CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2
... , NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. ... Officer of BioMarin, will present a company update at the Morgan Stanley ... 1:35 p.m. ET. , , Interested parties ... investor section of the BioMarin website, www.BMRN.com . ...
... , SAN DIEGO, Sept. 8 eBioscience Corporation, a ... the acquisition of NatuTec GmbH, a leading distributor of high-quality biological ... , "For the past 10 years, NatuTec has ... R. Nelson, CEO of eBioscience. "The NatuTec acquisition provides eBioscience ...
... LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- ... a,U.S. pharmaceutical company with its principal operations in the ... for,fiscal year 2009. The Company expects to meet ... revenue and operating income of $40 to $43 million ...
Cached Biology Technology:BioMarin to Present at the Morgan Stanley Healthcare Conference 2eBioscience Corporation Acquires NatuTec GmbH 2Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 2
(Date:9/16/2014)... YORK (17 September, 2014)More than $100 trillion in ... of annual carbon dioxide (CO2)a 40 percent reduction ... 2050 if the world expands public transportation, walking ... report released by the University of California, Davis, ... (ITDP). , Further, an estimated 1.4 million ...
(Date:9/16/2014)... its own bacterial identity. That,s the conclusion of University ... studied the genetic fingerprints of bacteria on 57 species ... study demonstrates for the first time that host plants ... possess very different microbial communities on their leaves," said ... in the UO,s Institute of Ecology and Evolution who ...
(Date:9/16/2014)... the Keystone XL pipeline (KXL) would likely increase oil ... researchers surveyed by the non-profit organization Near Zero. The ... Climate Impact," and includes both supporters and opponents of ... oil sands could lead to significantly higher greenhouse gas ... markets respond. , "This report examines three main ...
Breaking Biology News(10 mins):Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Microbiome research shows each tree species has a unique bacterial identity 2Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... For the first time in nearly a century drinkers will ... heritage barley from the Victorian period. Old varieties ... the John Innes Centre revived Chevallier from the institute,s Genetic ... records indicate that the variety produced premium quality malt and ...
... analysis, carbon dioxide removal could be used under certain ... but it would not replace the bulk of actual ... allows to separate emissions control from the time and ... important for climate protection," says lead-author Elmar Kriegler. "You ...
... "Many of the great whales which once populated the oceans ... commercial hunting. The committee also worried about how tuna fishing ... And they considered reports about seal hunting and the decline ... October of that year, Congress passed the Marine Mammal Protection ...
Cached Biology News:Cheers to better beer and disease resistance 2CO2 removal can lower costs of climate protection 2CO2 removal can lower costs of climate protection 3Sea mammals find US safe harbor 2Sea mammals find US safe harbor 3Sea mammals find US safe harbor 4